WEREWOLF THERAPEUTICS, INC. Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized of $1.30 million for the 12-month period ending 2024-12-31, per its S-4 filed 2026-09-22.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2024-03-31 was $400.00K, a 82.61% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2023-03-31 was $2.30M.
- WEREWOLF THERAPEUTICS, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2023 was $6.70M.
- WEREWOLF THERAPEUTICS, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2022 was $0.00.
| Period end | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 3 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 6 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 9 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.30M S-4 · filed 2026-09-22 | |||
| 2024-09-30 | $1.30M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $1.30M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $400.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $6.70M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $5.90M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $5.30M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $2.30M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |